Reference values for urinary oxalate, calcium, citrate, uric acid, phosphate, magnesium, sulphate and sodium in biochemistry students at Universidad Nacional del Litoral, Argentina
Abstract
Introduction: Urolithiasis (UL) is a common disease whose incidence increased in the last quarter of the twentieth century. Metabolic evaluation is necessary for diagnosis, which requires the establishment of reference values (RV) for the population in question. Objective: To determine the RV for calcium, oxalate, citrate, uric acid, phosphate, magnesium, sulphate and sodium in 24-hour urine belonging to students from the School of Biochemistry and Biological Sciences at Universidad Nacional del Litoral, province of Santa Fe, Argentina. Once RV were established, a frequency of alterations was determined and then compared with literature data. Methods: The NCCLSC28-A3 guideline (2008) was used. The study group included 69 students. The enzymatic colorimetric method, a Metrolab 1600 plus spectrophotometer and a DIESTRO ionselective electrode were also employed. Results: The RV found (95 % CI) were the following: oxalate, 1.96-45.08; calcium, 20.65-250.74; citrate, 112.78-666.01; uric acid, 58.73-782.17; phosphate, 238.37-1051.44; magnesium, 28.7-146.67, all these values expressed as mg/24h; sulphate, 3.15-25.18 mmol/24h, and sodium, 42.81-285.3 mEq/24h. These findings emerged as well: hyperoxaluria, 3 %; hypercalciuria 12 %; hypocitraturia, 3 %; hyperuricosuria, 6 %; hyperphosphaturia, 6 %; hypomagnesuria, 6 %; hypernatriuria, 7 %, and hypersulphaturia, 0 %. When RV were compared, some analyte levels were similar and others showed a considerable difference. Conclusions: The diagnosis of UL through the study of metabolic changes is different according to the reference value used. Applying reference values established for other populations, including those of commercial kits manufacturers, may lead to a diagnosis which does not match the clinical condition of the patient.
References
Spivacow FR, Del Valle EE, Negri AL, Fradinger E, Abib A, Rey P. Biochemical diagnosis in 3040 kidney stone formers in Argentina. Urolithiasis. 2015;43(4):323-30.
Siener R. Dietary factors. En: Rao NP, Preminger GM, Kavanagh JP, ed. Urinary tract stone disease. London: Springer, 2011; pp. 113-24.
Brikowski TH, Lotan Y, Pearle MS. Climate-related increase in the prevalence of urolithiasis in the United States. Proc Nat AcadSci USA. 2008;105(28):9841-46.
Pindulli I, Spivacow R, Del Valle E, Vidal S, Negri AL, Previgliano H, et al. Prevalence ofurolithiasis in the autonomous city of Buenos Aires, Argentina. Urol Res. 2006;34(1):8-11.
Sánchez A, Sarano D, Del Valle E. Nefrolitiasis. Fisiopatología, evaluación metabólica y manejo terapéutico. Actual Osteol. 2011;7(3):195-234.
Arrabal Martín M, Fernández Rodríguez A, Arrabal Polo MA, Ruíz García MJ, Zuluaga Gómez A. Estudio de factores físico-químicos en pacientes conlitiasis renal. Arch Esp Urol. 2006;59(6):583-94.
Curham GC. Epidemiology. En: Rao NP, Preminger GM, Kavanagh JP, ed. Urinary tract stone disease. London: Springer, 2011; pp. 3-7.
Defining, establishing, and verifying reference intervals in the clinical laboratory: approved guideline [Internet]. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2010. (CLSI Document; EP28-A3c). Disponible en: https://clsi.org/media/1421/ep28a3c_sample.pdf [consulta: abr. 2017].
Wu AHB. Tietz clinical guide to laboratory tests. 4th ed. St. Louis: Saunders/Elsevier, 2006. 1798 p.
Coll Sangrona E, Bónoli S, Jorquera A. Valores de referencia de citrato y oxalato urinarios para habitantes del área metropolitana del Estado Anzoátegui, Venezuela. Interciencia 2001;26(3):122-5.
Pak CY, Skurla C, Harvey J. Graphic display of urinary risk factors for renal stone formation. J Urol. 1985;134(5):867-70.
Wilson DM, Liedtke RR. Modified enzyme-based colorimetric assay of urinary and plasma oxalate with improved sensitivity and no ascorbate interference: reference values and sample handling procedures. Clin Chem. 1991;37(7):1229-35.
Welshman SG, McGeown MG. Urinary citrate excretion in stone-formers and normal controls. Br J Urol. 1976;48(1):7-11.
Lancina Martín JA, Rodríguez-Rivera García J, Novás Castro S, Rodríguez Gómez I, Fernández Rosado E, Álvarez Castelo L, et al. Factores de riesgo metabólico en urolitiasis cálcica según el sexo y edad de los pacientes. Actas Urol Esp. 2002;26(2):111-20.
Mayo Medical Laboratories. Test ID: CITR. Citrate Excretion, 24 Hour, Urine [Internet]. Disponible en: http://www.mayomedicallaboratories.com/test-catalog/Overview/9329 [consulta: abr. 2017].
Curcio R, Stettler H, Suter PM, Aksözen JB, Saleh L, Spanaus K, et al. Reference intervals for 24 laboratory parameters determined in 24-hour urine collections. Clin Chem Lab Med. 2016;54(1):105-16.
Hess B. Metabolic syndrome, obesity and kidney stones. Arab J Urol. 2012;10(3):258-64.
Negri AL, Spivacow FR, Del Valle EE. La dieta en el tratamiento de la litiasis renal bases fisiopatológicas. Medicina (B. Aires). 2013;73(3):267-71.
Heilberg IP, Goldfarb DS. Optimum nutrition for kidney stone disease. Adv Chronic Kidney Dis. 2013;20(2):165-74.
Del Valle EE, Spivacow F, Negri AL. Citrato y litiasis renal. Medicina (B. Aires). 2013;73(4):363-8.
Bordier P, Ryckewart A, Gueris J. On the pathogenesis of so-called idiopathic hypercalciuria. Am J Med. 1977;63(3):398-409.
Semins M, Matlaga B. Blood and urinary test in stone formers. En: Rao NP, Preminger GM, Kavanagh JP, ed. Urinary tract stone disease. London: Springer, 2011; pp. 369-74.
Pinto B. Litiasis renal. Barcelona: Salvat, 1976. 355 p.
Johansson G, Backman U, Danielson BG, Fellström B, Ljunghall S, Wikström B. Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide. J Urol. 1980;124(6):770-4.
